CrossBridge Bio, Inc., a pre-clinical biotechnology company pioneering the development of next-generation dual-payload ...

Eli Lilly's acquisition spree shows no sign of stalling, although the Big Pharma is keeping the terms of its latest buy ...

CE-Ventures, the corporate venture capital arm of the UAE-based investment firm Crescent Enterprises, has announced that its ...

Eli Lilly, the maker of the popular GLP-1 injectable Mounjaro, has invested heavily in Houston as a biotechnology hub.

CrossBridge Bio develops a dual-payload ADC technology created by Kyoji Tsuchikama at the University of Texas Health Science ...

Preview this article 1 min CrossBridge Bio is developing unique methods to transport chemotherapy to cancer cells, and its ...

CrossBridge Bio, a privately held biotech focused on developing cancer drugs, announced on Tuesday an agreement to be acquired by Eli Lilly (LLY) in an all-cash deal worth up to $300M. The ...

HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, a biotechnology company pioneering dual-payload antibody-drug conjugates (ADCs) as targeted cancer therapies, today announced the closing of a $10 million ...

CrossBridge Bio, a biotechnology company developing next-generation antibody-drug conjugates based on discoveries by ...

Innovative biotechnology company CrossBridge Bio to be acquired by US pharmaceutical major Eli Lilly in up to USD 300 million ...

CE-Ventures, the corporate venture capital arm of Crescent Enterprises, on Tuesday announced that its portfolio company CrossBridge Bio has entered into a definitive agreement to be acquired by US pha ...

CrossBridge Bio’s innovative approach to create stable, multi-loaded antibody–drug conjugates is set to generate a suite of first-in-class and best-in-class cancer therapies. Antibody–drug conjugates ...